Corrections:

Kazumasa Sekihara^1,2, Kaori Saitoh¹, Lina Han³, Stefan Ciurea³, Shinichi Yamamoto^1,2, Mika Kikkawa⁴, Saiko Kazuno⁴, Hikari Taka⁴, Naoko Kaga⁴, Hajime Arai⁴, Takashi Miida¹, Michael Andreeff³, Marina Konopleva³, Yoko Tabe^1,3,5

¹ Department of Laboratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan
² Leading Center for the Development and Research of Cancer Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan
³ Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
⁴ Laboratory of Proteomics and Biomolecular Science, Research Support Center, Juntendo University Graduate School of Medicine, Tokyo, Japan
⁵ Department of Next Genertion Hematology Laboratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan

Published: November 26, 2019

This article has been corrected: Due to errors in image assembly, a western blot (TSC2) in Figure 3B was accidentally duplicated. The corrected Figure 3 is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2017; 8:34552–34564. DOI: https://doi.org/10.18632/oncotarget.16602.

Figure 3: Molecular pathways affected by KPT-185 and AZD-2014 in MCL cells. After treatment for 24 hours (A), and 3 or 24 hours (B) with KPT-185, AZD-2014, or KPT-185+AZD-2014 (combination) at indicated concentrations, the cells indicated were subjected to lysis and immunoblot analysis. The results are representative of three independent experiments, and the intensity of each immunoblot signal compared to that of α-tubulin was quantified using ImageJ software; the quantity is shown directly under each blot.